PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Material Modification to Rights of Security HoldersItem 3.03
| (4) | A proposal to authorize the Company’s board of directors, in its discretion but prior to the annual meeting of the Company’s stockholders in 2019, to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1-for-4 to 1- for-10, such ratio to be determined by the board of directors and included in a public announcement. |
| (5) | A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, if and only if Proposal 3 and Proposal 4 are both approved and implemented, a reduction in the total number of authorized shares from 200,000,000 to 100,000,000. |
| (6) | Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018. |
|
For |
Against |
Abstain |
|
26,147,732 |
7,031,471 | 320,799 |
| (5) | A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, if and only if Proposal 3 and Proposal 4 are both approved and implemented, a reduction in the total number of authorized shares from 200,000,000 to 100,000,000: |
|
For |
Against |
Abstain |
|
29,003,660 |
3,941,747 | 554,595 |
| (6) | Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2017: |
|
For |
Against |
Abstain |
|
30,919,104 |
1,660,345 | 920,553 |
The results reported above are final voting results. No other matters were considered or voted upon at the meeting.
| Item 3.03 | Financial Statements and Exhibits. |
Pulmatrix, Inc. ExhibitEX-3.1 2 d602014dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PULMATRIX,…To view the full exhibit click here
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
